WEW GmbH’s Post

Life Science experts Adrian Toutoungi and Nicholas Vollers, review the key considerations from the Bruntwood SciTech event, hosted at our Cambridge office, for TechBio investors, CEOs and founders considering their exit strategy: https://bit.ly/430qo1G   Key takeaways include the importance of defining your product, an analysis of the types of exit opportunities available to TechBio companies, considerations when valuing assets and platforms, and how to approach a pharma collaboration.   #LifeSciences #TechBioExits #TechBioInvestors #PrivateWealth

🚀 Exciting news! 🚀 Thrilled to announce that I'll be sharing insights on a panel discussion at BioFIT in Marseille next week! 🌐 Join me as we delve into the dynamic world of biotech spin-outs and explore the fascinating journey "From lab to start-up." 🔬 Panel Topic: "From Lab to Start-Up: Let’s hear about successful spin-out journeys" 🌱 Navigating the spin-off roadmap: join me and fellow life science professionals as we unravel the strategies and lessons learned from successful biotech spin-outs. We'll be tackling crucial questions: 🔍 License or Launch: How do you decide whether to license a technology to an existing company or take the plunge and set up a spin-off? Let's explore the key considerations and decision-making factors. 🔄 The spin-off blueprint: What are the critical steps and challenges in spinning out a company based on academic research? Get ready for a deep dive into the intricacies of transforming groundbreaking research into a thriving start-up. Looking forward to a dynamic discussion! See you in Marseille! 👋🔬✨ #BioFIT #biotech #lifesciences #innovation #startupsuccess #spinoff

Synbiobeta last week was awesome! Maybe one of the best conferences I have attended. Not only were there talks by great scientists like Paul Stamets 🍄 and Craig Venter (picture below), but I reconnected with fermentation people at Genencor/DuPont/IFF, and BASF. Furthermore, I was able to meet many other innovators/service providers/investors during the conference. I feel very blessed to have spent two decades in this field. Although summarizing what I saw in bullet points is difficult, here it goes: • The conference felt very commercial in comparison to when it started, and not in a bad way. This is an indication that biotech has evolved over the past decade from the abstract or medical to the very practical. • The ecosystem is vibrant. There are many start-ups, service providers, innovators and investors from different countries all under one roof. To be candid, I was gladly surprised to see a couple of the Fortune 500 companies I worked for in the conference. • AI 🧠 is impacting everything including biotech. Although there are a lot of initiatives only time will tell which ones are the ones that will pan out commercially. Huge shout-out to Ginkgo Bioworks, Inc. and SynBioBeta for providing our start-up with a grant so that we could attend. I won't tag names, but building a start-up, just like raising a child 👶, takes a village. #synbio #synbiobeta #biotech #fermentation

I'm attending #analytica this week and I look forward to reconnecting with familiar faces and meeting new #biotech and #lifesciences enthusiasts. Whether you're an attendee, exhibitor, or industry expert, I'd love to connect and exchange insights. See you there!  #labinstruments #labtech #ResearchAndDevelopment #dll 

Hold onto your lab coats, we just launched our new Bio-Tech R&D page on our website! 🥼✨ Join us on a journey through the realms of innovation, where data-driven discoveries and biotech brilliance collide. Check it out: https://lnkd.in/dbrerGJz #BioInnovators #BioTechBreakthroughs #RnDInnovation #DataRevolution #InnovateWithData #TechInBiotech #InnovationStation #Scieline #ScielineWebsite

🎉 Newlab Member News Alert! 🎉 Congratulations to Caladan Bio on the launch of The Caladan 250 and on securing a $5M seed round led by Twelve Below with participation from Lerer Hippeau, Collaborative Fund, Wireframe Ventures, Ritual Capital and Factorial! About the Caladan 250: The Caladan 250 is a high throughput benchtop bioreactor system designed to increase experimentation throughput and enhance data capture - all while leveraging AI and ML. "As the tools to edit cells become commonplace, the focus needs to shift to optimizing biomanufacturing. At Caladan, we believe that for synthetic biology companies, the process is the product," says Michael Kobida, Co-Founder and CEO of Caladan Bio. Join us in celebrating this milestone achievement with Caladan Bio! Learn how you can join Newlab’s community of founders changing the world: https://lnkd.in/gbNRFZs6 Read more about Caladan's last round here: https://lnkd.in/gh8PxTgB

Extremely topical #webinar today from Inpart ahead of #BIO2024 with helpful insights from J&J, especially on how #biotechs can improve both their outreach to and #partnering meetings with prospective #pharma #licensing partners. A few key points: 1. Focus on the science in your request for the meeting. 2. Clearly articulate how your science is novel and transformative, and the problem you're trying to solve. 3. Find a partner that shares your values. Look for a cultural fit that encourages a meaningful and long-term partnership.

Last week, we were joined by Enveda Biosciences' Director of Operations, Joel Basken, and Nicolette Surges, their Lab Manager, to talk about the importance of a supportive and integrated tech stack for a growing lab. 💻 🌱 🔬 If you missed our webinar, watch the recording to hear real-life stories and get actionable tips on: - How to recognize triggers telling you it’s time to level up your tech solution. - How to avoid costly mistakes when your early-stage lab starts to grow. - How to build a mature ecosystem of tech tools that will support your lab's growth rather than hinder it. The on-demand webinar is available now: https://lnkd.in/e4dMGeWH #ZAGENOwebinar #techstack #labsupplies #lifescience #biotech #techtips

🧬 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝟮𝟬𝟮𝟯-𝟮𝟰: 𝗵𝗼𝘄 𝘁𝗼 𝘀𝘂𝗿𝘃𝗶𝘃𝗲 𝗱𝘂𝗿𝗶𝗻𝗴 𝘁𝗼𝘂𝗴𝗵 𝘁𝗶𝗺𝗲𝘀?  Great panel discussion led by Marc-Olivier Bévierre  during LSX - partnering for Life Science eXecutives Investival Showcase in London. 🎯“𝘚𝘶𝘳𝘷𝘪𝘷𝘦 𝘶𝘯𝘵𝘪𝘭 𝘺𝘰𝘶 𝘨𝘦𝘵 𝘨𝘰𝘰𝘥 𝘱𝘪𝘷𝘰𝘵𝘢𝘭 𝘥𝘢𝘵𝘢” was the key message, as both VCs and Pharma are reluctant today to invest earlier. But for those who reach that Graal, there is still plenty of money out there. 💡For those who are not there yet, there are solutions: operational efficiency, portfolio rationalization, biotech-biotech M&A; but all this requires to be creative and prepared to make difficult decisions. Thank you Tim Haines , Jasper Bos and Gonzalo Garcia for the enlightening discussions, and to our Cencora colleagues Sandra Salama Anderson , Guillaume Nebout - Pharm D, MBA , Gert Jan Van Der Hulst and Richard Ogborne. #transforminghealthcare #Biotechcommercialisation